This activity is jointly provided by the Postgraduate Institute for Medicine.

This activity is sponsored by the National Lipid Association.

Earn 28+ CME/CE Credits

Conference
August 26–28, 2016

Pre-Conference Courses
August 25–26, 2016

Omni Amelia Island Plantation Resort
39 Beach Lagoon Rd
Amelia Island, FL 32034

facebook.com/nationallipid

twitter.com/nationallipid

instagram.com/nationallipid

Linkedin
linkedin.com/national-lipid-association

clinical lipid update
AUGUST 26–28
2016
AMELIA ISLAND, FL

Hosted by the Southeast and Northeast Chapters

Register at: lipid.org/fallclu
Attend the Fall Clinical Lipid Update (CLU) taking place August 26–28 at the beautiful Omni Amelia Island Plantation Resort.

This year’s Fall CLU will be a practice-changing experience that will elevate your patient care. World-renowned speakers are confirmed for this cutting-edge and unique program that will discuss novel targets of therapy, team-based clinical care approaches, and identification of rare triglyceride disorders.

Peter W. F. Wilson, MD, will be speaking in the first session on practical insights into clinical prevention and dyslipidemia management. Michael Ozner, MD, will discuss the role of omega-3 fatty acids in the treatment and prevention of CVD on Saturday morning. In the afternoon, Michael J. Koren, MD, will give an update on the evolving line of lipid altering medications. Therapeutic options for triglyceride lowering will be addressed by Dave L. Dixon, PharmD.

Register today for the Fall CLU to gain real-world perspective on how to manage your patients and overcome common obstacles in your practice. Connect with renowned faculty and your colleagues to share ideas and get your questions answered.
KEYNOTE: Primary Prevention and the Challenge of Early Intervention for the Clinician

Neil J. Stone, MD, FNLA*
Medical Director, Center for Vascular Disease
Bluhm Cardiovascular Institute
Bonow Professor of Medicine
Northwestern University’s Feinberg School of Medicine
Chicago, IL

Friday, August 26
4:00–4:30 PM
General Session Room

KEYNOTE: Regression of Atherosclerosis: The Journey from the Liver to the Plaque and Back

Edward Fisher, MD, PhD, FNLA
Director, The Lipid Treatment and Research Center
Professor of Cardiovascular Medicine
New York University
New York, NY

Saturday, August 27
8:00–8:45 AM
General Session Room

Cardinal events in atherogenesis are the retention of apolipoprotein B (apoB1)–containing lipoproteins in the arterial wall and the inflammatory reactions of macrophages to these particles. My laboratory has focused on two areas related to these events, namely, the regulation of the production of apoB lipoproteins by the liver as well as the regression of atherosclerosis by the reversal of the inflammatory state of plaque macrophages. Insights from pre-clinical and clinical studies will be presented and considered in the context of current and envisioned modalities intended to lower cardiovascular disease risk.

KEYNOTE: Statins and Type 1 Diabetes Mellitus: When and How?

Robert H. Eckel, MD, FNLA*
Charles A. Boettcher Endowed Chair in Atherosclerosis
Professor of Medicine
Division of Endocrinology, Metabolism and Diabetes Cardiology Professor of Physiology and Biophysics
Program Director
Adult General Clinical Research Center
University of Colorado Anschutz Medical Campus
Aurora, CO

Sunday, August 28
9:00–9:40 AM
General Session Room

Type 1 diabetes mellitus (T1DM) is well recognized to be associated with a higher incidence and prevalence of atherosclerotic cardiovascular disease (ASCVD). However, randomized clinical trials in which risk factors for ASCVD events, including lipids, have been modified are nonexistent for T1DM patients. Thus, any model that attempts to define risk such as the Steno Risk Engine and the Swedish National Diabetes Register (NDR) are based almost entirely on observational data. However, the Cholesterol Treatment Trialists’ (CTT) Collaborators have analyzed data from 18,686 individuals with diabetes (1466 with T1DM and 17,220 with T2DM) in the context of a further analysis of 71,370 without diabetes in 14 randomized trials of statin therapy. In patients labeled as T1DM, there was some limited direct evidence of benefit in (0.79, 99% CI 0.62–1.01; p=0.01) (Lancet 371:12-18, 2008). However, the number of patients with T1DM varied from 0% (3 trials) to 13.3% with only one trial including more than 5% and average age of T1DM patients was 55±11 years. Many questions related to statins in T1DM arise: when should statins be initiated, and is that age dependent or duration of T1DM dependent? How much other risk factors should be taken into consideration? What about dosage? Is the atherosclerotic process the same in T1DM and T2DM?

* Diplomate, American Board of Clinical Lipidology
## AGENDA

### Friday, August 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Session I: Practical Insights into Clinical Prevention and Dyslipidemia Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45–4:00 PM</td>
<td>Presidents Welcome &amp; Introductions and ARS Questions</td>
</tr>
<tr>
<td>4:00–4:30 PM</td>
<td><strong>KEYNOTE:</strong> Primary Prevention and the Challenge of Early Intervention for the Clinician Neil J. Stone, MD, FNLA*</td>
</tr>
<tr>
<td>4:30–5:00 PM</td>
<td>Is Lower Better for LDL or Is There a “Sweet Spot?” — The Latest Controversy Alan S. Brown, MD, FACC, FAHA, FNLA*</td>
</tr>
<tr>
<td>5:00–5:30 PM</td>
<td>Type 2 Diabetes, Metabolic Syndrome, and Dyslipidemia: Where Does the Risk Lay? Peter W. F. Wilson, MD, FNLA*</td>
</tr>
<tr>
<td>5:30–6:00 PM</td>
<td>Q&amp;A Panel and ARS Questions</td>
</tr>
<tr>
<td>6:00–7:00 PM</td>
<td>Welcome Reception in Exhibit Hall</td>
</tr>
</tbody>
</table>

### Saturday, August 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Session II: Technology and Fatty Acids: Meeting the Players in CVD Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–7:50 AM</td>
<td>Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td>7:50–8:00 AM</td>
<td>Morning Notes &amp; ARS Questions</td>
</tr>
<tr>
<td>8:00–8:45 AM</td>
<td><strong>KEYNOTE:</strong> Regression of Atherosclerosis: The Journey from the Liver to the Plaque and Back Edward Fisher, MD, PhD, FNLA</td>
</tr>
<tr>
<td>8:45–9:10 AM</td>
<td>Measuring Regression of Coronary Atherosclerosis Through Imaging Allen J. Taylor, MD, FACC, FAHA</td>
</tr>
<tr>
<td>9:10–9:35 AM</td>
<td>Role of Omega-3 Fatty Acids in the Treatment and Prevention of CVD Michael Ozner, MD, FACC, FAHA</td>
</tr>
<tr>
<td>9:35–9:55 AM</td>
<td>Q&amp;A Panel and ARS Questions</td>
</tr>
<tr>
<td>9:55–10:20 AM</td>
<td>Break in Exhibit Hall</td>
</tr>
</tbody>
</table>

### Session III: Understanding the Role of Nutrition in CV Health

<table>
<thead>
<tr>
<th>Time</th>
<th>ARS Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20–10:25 AM</td>
<td>Are We Ready for Personalized Nutrition Counseling for CVD Health? Catherine Christie, PhD, RND, LDN, FADA, FAND</td>
</tr>
<tr>
<td>10:25–10:50 AM</td>
<td>Imbalanced Insulin Action in Chronic Overnutrition: Clinical Harm, Molecular Mechanisms, and a Way Forward Kevin Jon Williams, MD</td>
</tr>
</tbody>
</table>

### Session IV: Debating the Nocebo Effect

<table>
<thead>
<tr>
<th>Time</th>
<th>The Nocebo Effect in the Context of Statin Intolerance—Pro Jonathan A. Tobert, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15–11:25 AM</td>
<td>The Nocebo Effect in the Context of Statin Intolerance—Con Beth A. Taylor, PhD</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Activity</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>11:35–11:45 AM</td>
<td>Rebuttal</td>
</tr>
<tr>
<td>11:45 AM–12:10 PM</td>
<td>Q&amp;A Panel and ARS Questions</td>
</tr>
<tr>
<td>12:10–12:20 PM</td>
<td>NLA News &amp; Notes</td>
</tr>
<tr>
<td>12:20–1:15 PM</td>
<td>Lunch in Exhibit Hall</td>
</tr>
<tr>
<td>1:15–1:20 PM</td>
<td><strong>Session V: The Future of Lipid-Lowering Therapies – Are We Ready?</strong></td>
</tr>
<tr>
<td>1:20–1:45 PM</td>
<td>ARS Questions</td>
</tr>
<tr>
<td>1:45–2:10 PM</td>
<td>Evolving Pipeline of Lipid Altering Medications</td>
</tr>
<tr>
<td>2:10–2:35 PM</td>
<td>Use of Pharmacometabolomics to Predict Statin Response–Are We Ready for Prime Time?</td>
</tr>
<tr>
<td>2:35–3:00 PM</td>
<td>Non-Lipid Issues with PCSK9s: Safety, Efficacy, and other Considerations–A Case Study</td>
</tr>
<tr>
<td>3:00–3:55 PM</td>
<td>Q&amp;A Panel and ARS Questions</td>
</tr>
<tr>
<td>3:55–4:00 PM</td>
<td>Break</td>
</tr>
<tr>
<td>4:00–4:25 PM</td>
<td><strong>Session VI: What You Need to Know About Triglyceride Management</strong></td>
</tr>
<tr>
<td>4:25–4:50 PM</td>
<td>ARS Questions</td>
</tr>
<tr>
<td>4:50–5:15 PM</td>
<td>Identification of Rare Triglyceride Disorders</td>
</tr>
<tr>
<td>5:15–5:40 PM</td>
<td>Therapeutic Options for Triglyceride Lowering</td>
</tr>
<tr>
<td>6:30–9:30 PM</td>
<td>Foundation of the NLA Event</td>
</tr>
<tr>
<td><strong>Sunday, August 28</strong></td>
<td></td>
</tr>
<tr>
<td>8:00–8:50 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:50–9:00 AM</td>
<td>Morning Notes and ARS Questions</td>
</tr>
<tr>
<td>9:00–9:40 AM</td>
<td><strong>KEYNOTE</strong>: Statins and Type 1 Diabetes Mellitus: When and How?</td>
</tr>
<tr>
<td>9:40–10:10 AM</td>
<td><strong>Session VII: Discussing Unknown Risk Factors with Your Patient</strong></td>
</tr>
<tr>
<td>10:10–10:40 AM</td>
<td>Genetic Testing and What Really Goes on: A Live Interview</td>
</tr>
<tr>
<td>10:40–11:00 AM</td>
<td>Erectile Dysfunction, Cardiovascular Risk, and Testosterone</td>
</tr>
</tbody>
</table>
Joyce L. Ross, CRNP, MSN, ANP, CLS, FPCNA, FNLA
President, National Lipid Association
Consultative Education Specialist
Cardiovascular Risk Intervention
University of Pennsylvania Health System—Retired
Philadelphia, PA

Christie M. Ballantyne, MD, FNLA*
Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, TX

Dave L. Dixon, PharmD, BCPS, CDE, CLS, AACC, FNLA†
Associate Professor, Ambulatory Care
Vice-Chair of Clinical Services
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University
School of Pharmacy
Richmond, VA

Daniel A. Duprez, MD, PhD, FAHA, FACC, FESC, FASH, FNLA
Professor of Medicine
Medical School, University of Minnesota
Director for Research of the Rasmussen Center for Cardiovascular Disease Prevention
Director of the Lipid Clinic
University Medical Center Fairview, Minnesota (FUMC)
Cardiologist at FUMC
Minneapolis, MN

Anne C. Goldberg, MD, FACP, FNLA**
President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Robert Greenfield, MD, FACC, FAHA, FNLA*
University of California, Irvine
Memorial Health Care Hospitals
Orange Coast Memorial Hoag Hospital
Newport Beach
Hoag Hospital
Irvine
Fountain Valley Regional Medical Center
Irvine, CA

Elizabeth J. Jackson, MSN, ACNS-BC, CLS, FNLA
CardioTexas
St. David’s Medical Center
Austin, TX

* Diplomate, American Board of Clinical Lipidology
† Clinical Lipid Update Program Faculty

The NLA invites speakers and guests to provide scientific medical opinion, which do not necessarily reflect the policy of the NLA. The schedule and faculty are subject to change.
PROGRAM FACULTY

Alan S. Brown, MD, FACC, FAHA, FNLA*
Executive Council Chair, National Lipid Association
Director, Division of Cardiology
Interventional Cardiologist
Midwest Heart Specialists
Clinical Associate Professor
Loyola University
Maywood, IL

Catherine Christie, PhD, RDN, LDN, FADA, FAND
Associate Dean, Brooks College of Health
Professor and Nutrition Graduate Program Director
University of North Florida
Jacksonville, FL

Rhonda Cooper-Dehoff, PharmD, FAHA
Associate Professor
College of Pharmacy
Associate Director
Center for Pharmacogenomics
University of Florida
Gainesville, FL

Robert H. Eckel, MD, FNLA*
Charles A. Boettcher Endowed Chair in Atherosclerosis
Professor of Medicine
Division of Endocrinology Metabolism and Diabetes
Cardiology Professor of Physiology and Biophysics Program Director
Adult General Clinical Research Center
University of Colorado
Anschutz Medical Campus
Aurora, CO

Edward Fisher, MD, PhD, FNLA
Director, The Lipid Treatment and Research Center
Professor of Cardiovascular Medicine
New York University
School of Medicine
New York, NY

Eugenia Gianos, MD, FACC, FASE, FNLA*
Assistant Professor
Department of Medicine
New York University Langone Medical Center
Center for the Prevention of Cardiovascular Disease
New York, NY

Ira J. Goldberg, MD, FNLA
Clarissa and Edgar Bronfman, Jr. Professor
Director, Division of Endocrinology, Diabetes and Metabolism
New York University Langone Medical Center
New York, NY

Robert A. Kloner, MD, PhD
Director, Cardiovascular Research Institute
Vice President of Translation
Huntington Medical Research Institutes
Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, CA

Michael J. Koren, MD, CPI, FACC
CEO and Director
Jacksonville Center for Clinical Research
Encore Research Group
Jacksonville, FL

Michael Miller, MD, FACC, FAHA*
Professor of Cardiovascular Medicine
Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD

Michael Ozner, MD, FACC, FAHA
Medical Director
Wellness & Prevention
Baptist Health South Florida
Miami, FL

Cynthia G. Rodriguez, DNP, ARNP, FNP-BC, CLS, FNLA
ARNP Cardiology
Watson Clinic
Lakeland, FL

Neil J. Stone, MD, FNLA*
Medical Director, Center for Vascular Disease
Bluhm Cardiovascular Institute
Bonaw Professor of Medicine
Northwestern University’s Feinberg School of Medicine
Chicago, IL

Amy C. Sturm, MS, LGC
Associate Professor, Internal Medicine
Wexner Medical Center at The Ohio State University
Division of Human Genetics
Columbus, OH

Lindsey Sutton
Degreed Nutritionist
Bakersfield, CA

Allen J. Taylor, MD, FACC, FAHA
Chief, Cardiology Division
Medstar Georgetown University Hospital
Medstar Washington Hospital Center
Medstar Heart and Vascular Institute
Professor of Medicine, Georgetown University
Washington, DC

Beth A. Taylor, PhD
Associate Professor
Kinesiology
University of Connecticut
Director of Exercise Physiology Research, Cardiology
Hartford Hospital
Hartford, CT

Jonathan Tobert, MD
Academic Visitor
Nuffield Department of Population Health
University of Oxford
Oxford, UK

Kevin Jon Williams, MD
Section Chief
Endocrinology, Diabetes and Metabolism Professor
Medicine Professor, Physiology Professor
Cardiovascular Research Center
Lewis Katz School of Medicine Temple University
Philadelphia, PA

Peter W. F. Wilson, MD, FNLA*
Professor of Medicine
Division of Cardiology
Emory University School of Medicine
Professor of Public Health
Rollins School of Public Health
Director, Epidemiology and Genomic Medicine
Atlanta VA Medical Center
Atlanta, GA

* Diplomate, American Board of Clinical Lipidology

Register early and save at lipid.org/fallclu
The NLA’s Lipid Academy provides a comprehensive, in-depth indoctrination to lipid science and is open to all health care professionals interested in developing a core competency in the diagnosis and treatment of dyslipidemia. The interactive course provides health professionals with the knowledge and tools necessary to work effectively in a lipid practice, and will serve as a preparatory course for the CLU and other advanced lipid training. Additionally, participants earn NLA endorsed lipid education credits that will help prepare for certification by the American Board of Clinical Lipidology (ABCL) or the Accreditation Council in Clinical Lipidology (ACCL). The Lipid Academy is offered as a 2-day course prior to each scientific meeting conducted by the NLA. For more information, visit lipid.org/lipidacademy.

FACULTY

Lori Alexander, MSHS, RD, CCRC, CLS, FNLA
Site Manager
St. Johns Center for Clinical Research
Ponte Vedra, FL

Michael J. Bloch, MD, FACP, FASH, FVM, FNLA*
Associate Professor
Department of Medicine, University of Nevada School of Medicine
Medical Director
Vascular Care, Renown Institute for Health and Vascular Health
Renown Regional Medical Center
Reno, NV

Ann Liebeskind, MD, FAAP*
Founder, Complex Lipids Clinic
Mobile Health Team
Neenah & Wauwatosa, WI

Joseph J. Saseen, PharmD, CLS, FNLA
Professor
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA*
President-Elect, National Lipid Association
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York University Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY

Harold E. Bays, MD, FNLA*
Secretary/Treasurer, National Lipid Association
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Alan S. Brown, MD, FACC, FAHA, FNLA*
Executive Council Chair, National Lipid Association
Interventional Cardiologist
Midwest Heart Specialists
Clinical Associate Professor
Loyola University
Maywood, IL

Anne C. Goldberg, MD, FACP, FNLA**
President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Terry A. Jacobson, MD, FNLA*
Professor of Medicine
Director, Office of Health Promotion and Disease Prevention
Emory University
Atlanta, GA

Kevin C. Maki, PhD, CLS, FNLA
Chief Science Officer
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL

Carl E. Orringer, MD, FACC, FNLA*
Immediate Past President, National Lipid Association
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL

* Diplomate, American Board of Clinical Lipidology

This intensive 2-day training course offers an in-depth review of the core curriculum in Clinical Lipidology for healthcare professionals who desire to practice at an advanced level within the field. The new case-based, interactive agenda will improve your clinical decision making skills and help prepare you for certification by the American Board of Clinical Lipidology (ABCL) or the Accreditation Council in Clinical Lipidology (ACCL). For those not preparing for certification, the course provides an excellent update and refresher on core concepts in Lipidology. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

For more information visit lipid.org/education/courses/masters.
Mini Golf Adventure with the Foundation

Join the Foundation of the National Lipid Association for a fun-filled evening of mini golf! Engage your peers in a friendly competition through 18 holes on the Heron Cove Adventure Golf course. The winning team will take home prizes and bragging rights. Enjoy a cash-bar, ping pong, and oversized board games on the course. A portion of the proceeds will be donated to the Foundation.

Heron Cove Adventure Golf
Saturday, August 27
6:30–8:30 PM
$40/person
Meet in the hotel lobby for a brief 3-5 minute walk to the mini golf course.

Welcome Reception
Friday, August 26
6:00–7:00 PM

Join your fellow colleagues for an opening reception on Friday evening in the exhibit hall. Mingle with exhibiting companies while enjoying tasty hors d’oeuvres and cocktails.

Access to this reception is included in the Fall CLU registration fee; guests with an exhibit hall pass are also welcome.
Omni Amelia Island Plantation Resort
39 Beach Lagoon Rd
Amelia Island, FL 32034

Meeting Room Rate: $189/night ++
Room Reservation Cut-Off-Date: July 25

Omni Amelia Island Plantation Resort is nestled on 1,350 acres at the tip of a barrier island just off the Northeast Florida coast. Enjoy luxurious oceanfront accommodations, world-class resort pools, championship golf, full-service spa, endless dining options, and family-friendly activities. Stroll 3.5 miles of pristine beach or spend some time in the fully equipped fitness center with a 20-yard indoor lap pool. The resort features more than 400 oceanfront guest rooms and suites with patios and balconies.

Travel Information:
Book your airfare on Delta and receive up to 5% off of your flight to Jacksonville, Florida. Book your flight on delta.com and enter NMNQ8 in the “offer” code box when searching for your flight. Discounts applicable for travel to and from Jacksonville between August 23–September 2.

The Jacksonville Airport is located 29 miles from the resort.

While on Amelia Island visit...

**Amelia Island Historic District**
Encompassing a 50-block area and listed on the National Register of Historic Places, Amelia Island’s Fernandina Beach Historic District is a local treasure. In this area south of Old Town, visitors will find excellent examples of late 19th and early 20th century architecture, from Italian to Beaux Arts to Victorian. For a unique view, take a walking, or trolley tour. Also stop by Fantastic Fudge for a delicious local treat where they make the fudge in house.

**Fort Clinch State Park**
2601 Atlantic Ave, Fernandina Beach, FL 32034
Built in 1847 on a site occupying military troops since 1736, kids can get a glimpse into the island’s past. Briefly occupied by Confederate troops during the Civil War, the fort was also used to during the Spanish American War. The park now offers guided tours, as well as a winding nature trail encircling a man-made pond.
**Target Audience**
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

**Type of Activity**
Live Activity
Knowledge

**Educational Objectives**
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

**Session I: Practical Insights into Clinical Prevention and Dyslipidemia Management**
- Review management strategies for the primary prevention of ASCVD
- Discuss how novel and emerging therapies can best be integrated into clinical practice
- Describe the pathophysiology of type 2 diabetes and metabolic syndrome, including the characteristic atherogenic dyslipidemia found in these patients

**Keynote Saturday:**
- Review the impact on cardiovascular risk of atherosclerotic plaque development and progression

**Session II: Technology and Fatty Acids: Meeting the Players in CVD Prevention**
- Review the use of non-invasive coronary and carotid imaging and its role for cardiovascular disease risk assessment
- Identify the impact of omega-3 fatty acids on lipids, lipoproteins and ASCVD risk reduction

**Session III: Understanding the Role of Nutrition in CV Health**
- Discuss the evidence that supports the benefits of personalized nutritional counseling and its impact on ASCVD, dyslipidemia, diabetes, metabolic syndrome, and obesity
- Describe the role of insulin in metabolic syndrome, obesity, and ASCVD risk

**Session IV: Debating the Nocebo Effect**
- Discuss current literature regarding statin medications and muscle related side effects

**Session V: The Future of Lipid-Lowering Therapies—Are We Ready?**
- Assess current and evolving perspectives on lipid altering medications
- Identify statin-influenced pathways that may contribute to variability in clinical efficacy, as well as to risk of adverse events
- Assess the safety and efficacy of lipid altering and non-lipid effects of PCSK9 inhibitors

**Session VI: What You Need to Know About Triglyceride Management**
- Discuss the genetic basis and mechanistic of inherited triglyceride disorders
- Discuss evidence regarding triglycerides as a risk factor for cardiovascular disease including the clinical implications for patient management
- Assess the status of current and emerging treatment options for lowering triglycerides

**Keynote Sunday:**
- Discuss the role of statin therapy in the management of patients with type 1 diabetes

**Session VII: Discussing Unknown Risk Factors with your Patient**
- Explain the role of the genetic counselor in the care of patients with inherited lipid disorders
- Identify the epidemiology and pathophysiologic links between erectile dysfunction and ASCVD risk
- Explain the role of testosterone therapy in the patient with or at risk for ASCVD

Register early and save at lipid.org/fallclu
Clinical Lipid Update

CE credit provided by Postgraduate Institute for Medicine

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I - Universal Activity Number 0809-9999-16-335-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education.

Keynote - Session I - Universal Activity Number 0809-9999-16-334-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Session II - Universal Activity Number 0809-9999-16-336-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

Session III - Universal Activity Number 0809-9999-16-337-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

Session IV - Universal Activity Number 0809-9999-16-338-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Session V - Universal Activity Number 0809-9999-16-339-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education.

Session VI - Universal Activity Number 0809-9999-16-340-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

Keynote - Session II - Universal Activity Number 0809-9999-16-362-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
For Registered Nurses and Nurse Practitioners only
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Criteria for Success:
A statement of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim form at www.lipid.org/cme for Pharmacists. Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of the continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support:
Full notification of commercial support will be provided in the activity syllabus.

NLA Lipid Academy

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, advance practice registered nurses, registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

Type of Activity
Application

Learning Objectives
At the conclusion of this activity, participants should be able to:
• Describe the functions and sources of cholesterol and triglycerides including the role of lipoprotein in atherosclerosis
• Explain the pathogenesis of atherosclerosis
• Identify the role of inflammation in atherosclerosis
• Discuss clinical trials including their role in lipid and lipoprotein treatment in cardiovascular prevention
• Review the clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
• Apply basic principles of statistics to enhance understanding of clinical trials related to lipid management
• Compare and contrast the effectiveness of available risk assessment instruments and markers in predicting CV risk in all population groups
• Identify primary and secondary causes of dyslipidemia
• Recognize the role of drug therapy in the management of dyslipidemia
• Review the mechanism of action, pharmacokinetics, and efficacy of available FDA approved drugs for the management of lipid disorders
• Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
• Describe the appropriate use of lipid-altering drugs in special populations
• Describe effective diet and lifestyle strategies for long-term obesity and dyslipidemia management
• Describe the association of specific dietary patterns such as increased sodium and sugar intake, and the increased risk for cardiovascular disease associated morbidity and mortality
• Compose a clinical case plan for reducing risk of CV events in patients with dyslipidemia
• Analyze case studies in lipid management to improve treatment and prevention of cardiovascular disease
• Analyze lipid cases for health professionals seeing patients with complex disorders
• Identify the management of dyslipidemia in special populations based on gender, culture, and disease variables
• Outline current guidelines on the management and treatment of patients with dyslipidemia

For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

For Registered Nurses and Nurse Practitioners only

Practice appropriate care and counsel for patients and their families

CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Day 1 Morning Session - Universal Activity Number - 0809-9999-16-032-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3.25 contact hour(s) (0.325 CEUs) of the Accreditation Council for Pharmacy Education.

Day 1 Afternoon Session - Universal Activity Number - 0809-9999-16-033-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 4.2 contact hour(s) (0.42 CEUs) of the Accreditation Council for Pharmacy Education.

Day 2 Morning Session - Universal Activity Number - 0809-9999-16-034-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.75 contact hour(s) (0.275 CEUs) of the Accreditation Council for Pharmacy Education.

Day 2 Afternoon Session - Universal Activity Number - 0809-9999-16-035-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.5 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 12.6 contact hours is provided by Postgraduate Institute for Medicine.

Day 1 Morning Session - Universal Activity Number - 0809-9999-16-032-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3.25 contact hour(s) (0.325 CEUs) of the Accreditation Council for Pharmacy Education.

Day 1 Afternoon Session - Universal Activity Number - 0809-9999-16-033-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 4.25 contact hour(s) (0.425 CEUs) of the Accreditation Council for Pharmacy Education.

Day 2 Morning Session - Universal Activity Number - 0809-9999-16-034-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.75 contact hour(s) (0.275 CEUs) of the Accreditation Council for Pharmacy Education.

Day 2 Afternoon Session - Universal Activity Number - 0809-9999-16-035-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.5 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

Register early and save at lipid.org/fallclcu
At the conclusion of this activity, participants should be able to:

**Learning Objectives:**
- Knowledge, Application
  - Explain lipoprotein metabolism and its role in the pathogenesis of atherosclerosis
  - Describe genetic disorders affecting lipoprotein metabolism
  - Describe the vascular biology and pathophysiology of atherosclerosis
  - Apply basic principles of evidence based medicine to enhance understanding of clinical trial results, methods for cardiovascular risk stratification, and applying new research into practice
  - Explain clinical practice guidelines, the different types of evidence used to make clinical guidelines, and the role of clinical judgment in applying guidelines to practice
  - Outline current issues and approaches to global cardiovascular risk assessment
  - Assess traditional and emerging biomarkers for the prevention and treatment of atherosclerotic cardiovascular disease
  - Review the role of adipokine and adipokine-like proteins in cardiovascular disease risk assessment and management
  - Identify the evidence base that supports current dietary recommendations for heart health
  - Describe effective diet and lifestyle interventions, weight management strategies for the management of dyslipidemia and cardiovascular risk
  - Identify how general dietary patterns and specific macronutrients fats, carbohydrates affect coronary heart disease and lipids
  - Explain how obesity and adiposopathy contribute to the metabolic syndrome and diabetes mellitus
  - Identify management strategies for the cardiometabolic risk factors of the metabolic syndrome
  - Review the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of lipid disorders
  - Assess the side effects of lipid-lowering drugs to encourage their safe use in cardiovascular disease prevention
  - Review clinical trials of lipid-lowering drug therapies used in cardiovascular disease prevention
  - Describe combination therapies for the management of complex lipid disorders and residual risk
  - Manage complex dyslipidemia and dyslipidemia in special populations

**For Registered Nurses and Nurse Practitioners only**
Provide appropriate care and counsel for patients and their families

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Lipid Association designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 16 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL0002.

American Academy of Family Physicians
This live activity, 2016 Masters in Lipidology Course, from 03/17/2016 - 08/26/2016, has been reviewed and is acceptable for up to 16.00 Elective credits by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Day 1 Morning Session - Universal Activity Number - 0809-9999-16-044-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 5.50 contact hours (1.50 CEU) of the Accreditation Council for Pharmacy Education.

Day 1 Afternoon Session - Universal Activity Number - 0809-9999-16-045-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.50 contact hours (0.50 CEU) of the Accreditation Council for Pharmacy Education.

Day 2 Morning Session - Universal Activity Number - 0809-9999-16-046-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 5.50 contact hours (1.50 CEU) of the Accreditation Council for Pharmacy Education.

Day 2 Afternoon Session - Universal Activity Number - 0809-9999-16-047-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.50 contact hours (0.50 CEU) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 15.5 contact hours is provided by Postgraduate Institute for Medicine. Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Day 1 Morning Session - 3.5 credits, Day 1 Afternoon Session - 5.4 credits, Day 2 Morning Session - 4.5 credits, Day 2 Afternoon Session - 2.5 credits.

For the advanced practice nurse, this activity has 3.4 contact hours of pharmacotherapy content.

“I am reinvigorated to move forward with my career as a Lipidologist.”
— Morton T. Saunders, Jr, DO

“I am already a lipid specialist, but I learned so much that I can apply to practice on Monday.”
— Brenda F. Rodi, FNP

“Really great meeting where you get to mingle with experts. A more effective learning experience than many large meetings.”
— Elaine Urbina, MD

“This was an outstanding educational experience. OUTSTANDING AND PERSONAL FACULTY.”
— Michael Doyle, MD

Register early and save at lipid.org/fallclu
BEFORE YOU GO

New in 2016: Mobile App

The National Lipid Association will be providing an app with onsite updates and educational content for attendees. Please check the website for information coming soon about how to download the app in preparation for the meeting. Make sure to bring your device because we will not be providing a printed syllabus. The app is compatible with laptops, tablets, and mobile devices.

Your Registration Includes:

• Access to all educational sessions
• Welcome Reception (hors d’oeuvres and cocktails)
• Breakfast on Saturday and Sunday
• Lunch on Saturday
• Meeting bag

Get Engaged

Be part of the conversation and stay in the know by following the NLA on Twitter, Instagram, Facebook, and LinkedIn. Use hashtag #NLAinAmelia when posting about the meeting.

NLA Members Save up to $400

Not yet a member? Join the National Lipid Association today and save up to $250 on your registration, when registering before June 30, or $200 when registering after the Early Bird rate ends. Learn more about NLA membership by visiting lipid.org/join.

NLA’s Trainee Travel Grant Program

Are you a fellow-in-training who has a focus in lipid management? Learn about the NLA’s trainee travel grant program! Fifteen grants are available for the NLA Lipid Academy course, each including a $500 travel grant and complimentary attendance to the Lipid Academy course — plus NLA membership for lipid focused fellows-in-training is always complimentary. Due to the popularity of the program, please act quickly and contact Amanda East at aeast@lipid.org for more information. Visit lipid.org/education/fellows for additional trainee opportunities.

facebook.com/nationallipid
twitter.com/nationallipid
instagram.com/nationallipid
linkedin.com/national-lipid-association

Register early and save at lipid.org/fallclu
# 2016 Clinical Lipid Update • August 26–28, 2016 • Omni Amelia Island Plantation Resort • Amelia Island, FL

<table>
<thead>
<tr>
<th>First Name</th>
<th>Middle Initial</th>
<th>Last Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mailing Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>State or Province</th>
<th>Zip</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phone</th>
<th>Emergency Contact/Phone</th>
<th>Cell Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

Check all that apply: □ MD/DO/PhD □ RN □ NP □ PA □ RPH □ PharmD □ RD □ Other ____________________________

**Guest name(s), if attending meeting:**

<table>
<thead>
<tr>
<th>Membership status:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

- □ I am currently a member.
- □ My application for membership has been submitted and confirmed.
- □ I will apply at lipid.org.
- □ Please send me membership information.

## Registration:

**Registration:** Registration and payment must be received no later than August 16, 2016. After this date, meeting materials and name badge cannot be guaranteed.

**Cancellation:** Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than July 29, 2016. This includes social events and guest fees. There will be a $100 fee for all cancellations.

**Special Needs:** __________________________________________

**ADA Compliance:** Attendees who need additional reasonable accommodations or who have special needs should contact the NLA at 904.998.0854.

*Master’s Course:* To purchase the NLA-SAPs please go to: lipid.org/education/nlasap.

**Trainee Rate:** Available for those individuals actively enrolled in a graduate or postgraduate training program for the treatment or investigation of lipid disorders and in pursuit of full credentialing in their specialized area of medical study. A letter from the program director or the school registrar must accompany the application.

**Registration Discount Disclaimer:** Discount codes cannot be retroactively applied to existing meeting registrations. The meeting discount codes are applicable to new registrants only.

## 3 Easy Ways To Register

- **Mail**
  - National Lipid Association
  - 6816 Southpoint Parkway, Suite 1000
  - Jacksonville, FL 32216

- **Fax**
  - NLA at 904.998.0855
  - Fax with credit card number and signature

- **Online**
  - lipid.org/fallclu

---

**Circle fee based on attendee type**

<table>
<thead>
<tr>
<th></th>
<th>NLA Member Early Bird Rate</th>
<th>NLA Member Discounted Rate</th>
<th>Non-Member Rate</th>
<th>Trainee Rate†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Lipid Update</td>
<td>$495</td>
<td>$545</td>
<td>$895</td>
<td>$75</td>
</tr>
<tr>
<td>August 26–28, 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masters in Lipidology Course*</td>
<td>$750</td>
<td>$750</td>
<td>$1250</td>
<td>$395</td>
</tr>
<tr>
<td>August 25–26, 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid Academy</td>
<td>$550</td>
<td>$550</td>
<td>$950</td>
<td>$0</td>
</tr>
<tr>
<td>August 25–26, 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Registration Fee Total**

$_______ $_______ $_______ $_______

**Special Events and Guest Fees**

- □ Foundation Event: Mini Golf
  - $40
  - X____ = $_______

- □ Exhibit Hall Pass-Guest(s)
  - $150
  - X____ = $_______

**Special Event and Guest Totals**

$_______

**Combined Total Fees**

$_______

**Payment Method**

- □ VISA □ MC □ AMEX □ Check  
  - Make checks payable to the NLA

<table>
<thead>
<tr>
<th>Credit Card #</th>
<th>Exp. Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name on Card</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>
Airline Discount

Book your airfare on Delta and receive up to 5% off of your flight to Jacksonville, Fla. Book your flight on delta.com and enter NMNQ8 in the “offer” code box when searching for your flight. Discounts applicable for travel to and from Jacksonville between August 23-September 2, 2016.